Skip to content
Inciteful Med

Subtypes & Antibodies: Your Personal Roadmap

Last updated:

Scleroderma has multiple subtypes, including localized (morphea) and systemic sclerosis (limited and diffuse). Your specific autoantibody profile—such as Anticentromere, Anti-Scl-70, or Anti-RNA Polymerase III—acts as a roadmap to predict potential organ risks and guide your treatment.

Key Takeaways

  • • Scleroderma is divided into localized forms (morphea) that affect mainly the skin, and systemic sclerosis which can affect internal organs.
  • • Systemic sclerosis includes limited cutaneous, diffuse cutaneous, and the rare sine scleroderma.
  • • Specific autoantibodies in your blood act as a predictive roadmap to indicate which internal organs are most at risk.
  • • Anticentromere antibodies are linked to pulmonary arterial hypertension, while Anti-Scl-70 strongly predicts interstitial lung disease.
  • • Anti-RNA Polymerase III carries a high risk for scleroderma renal crisis, requiring strict daily blood pressure monitoring.

Scleroderma is not a single disease, but a collection of conditions that range from small skin patches to widespread organ involvement. Understanding your subtype and your autoantibody profile is the most important step in your care because these two factors act as a “roadmap,” telling your doctor which organs need the most protection [1][2].

Localized Scleroderma (Morphea)

Localized scleroderma, also called morphea, is typically confined to the skin and underlying tissues. It rarely affects internal organs [3]. The main types include:

  • Plaque Morphea: The most common form, appearing as oval, firm patches of skin often surrounded by a “lilac ring” of inflammation [4][5].
  • Linear Scleroderma: Appears as “bands” of thickened skin, often on a limb. It can affect the muscle and bone underneath [6].
  • En Coup de Sabre (ECDS): A specific type of linear scleroderma on the forehead or scalp that looks like a “saber cut.” Because it is near the head, doctors may monitor for neurological symptoms like headaches or seizures [7][8].

Systemic Sclerosis (SSc)

Systemic Sclerosis is the form that can involve internal organs. It is divided into three main categories based on where the skin thickening is located [1]:

  • Limited Cutaneous (lcSSc): Skin thickening is “limited” to the hands, feet, and face (areas below the elbows and knees). It usually progresses slowly [1].
  • Diffuse Cutaneous (dcSSc): Skin thickening can occur anywhere on the body, including the upper arms, thighs, and trunk. This subtype often moves more quickly and has a higher risk of early organ involvement [1][9].
  • Sine Scleroderma (ssSSc): A rare form where the patient has internal organ involvement and specific antibodies but no visible skin thickening [10][11].

Autoantibodies: Your Risk Roadmap

Your blood contains autoantibodies—proteins that mistakenly attack your own tissues. In scleroderma, three specific antibodies are the most important for predicting your future health [1]:

Autoantibody Most Common Subtype Primary Risk Area
Anticentromere (ACA) Limited (lcSSc) PAH: Higher risk for high blood pressure in the lungs (Pulmonary Arterial Hypertension) [1][12].
Anti-Scl-70 (ATA) Diffuse (dcSSc) ILD: Very strong predictor for Interstitial Lung Disease (scarring of the lungs) [2][13].
Anti-RNA Polymerase III Diffuse (dcSSc) SRC: Highest risk for Scleroderma Renal Crisis (sudden kidney failure/high blood pressure). It also requires temporary, close monitoring for cancer risk [14][15][16].

Why This Matters

Knowing your profile allows for “preventative” medicine. For example, if you are positive for Anti-RNA Polymerase III, your doctor will have you monitor your blood pressure daily at home to catch a renal crisis before it causes damage [15]. If you are positive for Anti-Scl-70, you will receive more frequent lung scans (HRCT) to catch lung scarring at its most treatable stage [13].

Frequently Asked Questions

What is the difference between limited and diffuse scleroderma?
Limited scleroderma usually causes skin thickening only on the hands, feet, and face, and progresses slowly. Diffuse scleroderma can cause skin thickening anywhere on the body, including the trunk and upper arms, and carries a higher risk of early internal organ involvement.
What does an Anti-Scl-70 positive test mean?
Testing positive for the Anti-Scl-70 autoantibody is associated with the diffuse subtype of systemic sclerosis. It indicates a higher risk of developing interstitial lung disease, meaning your doctor will likely recommend frequent lung scans to catch any scarring early.
Why do I need to check my blood pressure every day if I have scleroderma?
If you test positive for the Anti-RNA Polymerase III antibody, you are at a higher risk for a sudden complication called scleroderma renal crisis. Daily blood pressure monitoring helps catch this kidney complication early before it causes permanent damage.
Can you have systemic sclerosis without skin thickening?
Yes, there is a rare subtype called sine scleroderma. Patients with this form experience internal organ involvement and test positive for specific scleroderma autoantibodies, but they do not develop the visible skin thickening seen in other subtypes.
What is en coup de sabre scleroderma?
En coup de sabre is a type of localized scleroderma that appears as a band of thickened skin on the forehead or scalp. Because of its location on the head, doctors carefully monitor patients for underlying neurological symptoms like headaches or seizures.

Questions for Your Doctor

  • • Which specific autoantibody did I test positive for (Anti-Scl-70, Anticentromere, or Anti-RNA Polymerase III)?
  • • Given my antibody profile, how often should I have pulmonary function tests and echocardiograms?
  • • Do I have limited cutaneous, diffuse cutaneous, or sine scleroderma, and how does that change my treatment plan?
  • • If I have the Anti-RNA Polymerase III antibody, what is your recommended protocol for cancer screening and blood pressure monitoring?
  • • For linear morphea/en coup de sabre: Do I need an MRI of my brain to check for involvement beneath the skin?

Questions for You

  • • Have you noticed skin tightening only on your hands and face, or is it also appearing on your upper arms, thighs, or trunk?
  • • Are you keeping a daily log of your blood pressure? (This is especially important if you have the diffuse subtype or certain antibodies).
  • • Have you experienced any 'invisible' symptoms like new headaches or vision changes that might suggest the disease is affecting deeper tissues?
  • • Do you have Raynaud's phenomenon (fingers changing color), or are your symptoms strictly limited to skin patches?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.

    Namas R, Elarabi M, Khan S, et al.

    Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.

    PMID: 37287950
  2. 2

    Antinuclear antibody pattern and autoantibody profiling of systemic sclerosis patients in a tertiary referral center in North India.

    Machhua S, Sharma SK, Kumar Y, et al.

    Pathology international 2022; (72(5)):283-292 doi:10.1111/pin.13221.

    PMID: 35319814
  3. 3

    Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

    Zhao M, Wu J, Wu H, et al.

    Clinical reviews in allergy & immunology 2022; (62(2)):273-291 doi:10.1007/s12016-020-08831-4.

    PMID: 33449302
  4. 4

    Recurrent Plaque Morphea Successfully Treated with PDO Mono Threads and Topical Tacrolimus Ointment.

    Sakhiya J, Sakhiya D, Dedakiya A, et al.

    The Journal of clinical and aesthetic dermatology 2020; (13(10)):38-41.

    PMID: 33584956
  5. 5

    Pseudohypertension-Like Presentation: An Exceptionally Rare Presentation in an Athletic Female Patient with Morphea.

    Al-Imam A

    Case reports in dermatological medicine 2016; (2016()):7027352 doi:10.1155/2016/7027352.

    PMID: 28127475
  6. 6

    [Localized scleroderma].

    Al-Gburi S, Kreuter A, Moinzadeh P

    Dermatologie (Heidelberg, Germany) 2024; (75(3)):197-207 doi:10.1007/s00105-024-05297-9.

    PMID: 38363312
  7. 7

    [En coup de sabre linear scleroderma with central nervous system involvement in a pediatric patient].

    Kulikova SL, Semashko MD, Levshuk ON, et al.

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2025; (125(10. Vyp. 2)):120-126 doi:10.17116/jnevro2025125102120.

    PMID: 41283843
  8. 8

    Linear Scleroderma En Coup de Sabre: A Case Series With Eyelid Involvement and Management.

    Kok LT, Malik M, Fayers T, et al.

    Ophthalmic plastic and reconstructive surgery 2025; (41(3)):e80-e85 doi:10.1097/IOP.0000000000002843.

    PMID: 39656045
  9. 9

    Systemic Sclerosis and Pulmonary Disease.

    Ngo K

    Advances in experimental medicine and biology 2021; (1303()):173-182 doi:10.1007/978-3-030-63046-1_10.

    PMID: 33788193
  10. 10

    Raynaud's Phenomenon and Pericardial Effusion Requiring Management with A Pericardial Window as the only Manifestations of Systemic Sclerosis without Scleroderma for over 10 Years, after which Pulmonary Hypertension Developed.

    Moriarty N, Vadiveloo TDV, Osman F, et al.

    European journal of case reports in internal medicine 2025; (12(11)):005866 doi:10.12890/2025_005866.

    PMID: 41229634
  11. 11

    Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.

    Chong WH, Saha BK, Beegle S

    The American journal of the medical sciences 2023; (365(2)):198-204 doi:10.1016/j.amjms.2022.01.023.

    PMID: 35276077
  12. 12

    Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes.

    Tieu A, Chaigne B, Dunogué B, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(5)) doi:10.3390/diagnostics12051067.

    PMID: 35626223
  13. 13

    Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

    Lescoat A, Roofeh D, Kuwana M, et al.

    Clinical reviews in allergy & immunology 2023; (64(3)):239-261 doi:10.1007/s12016-021-08891-0.

    PMID: 34468946
  14. 14

    Evaluation of malignancy risk in patients with SSc by autoantibody profile: a systematic review with meta-analysis.

    Towachiraporn K, Sanyanusin W, Rojhirunsakool S, et al.

    Rheumatology advances in practice 2025; (9(4)):rkaf115 doi:10.1093/rap/rkaf115.

    PMID: 41170152
  15. 15

    Kidney Transplantation in a Patient with Scleroderma.

    Bear L, Agmon Levine N, Ghinea R, et al.

    The Israel Medical Association journal : IMAJ 2024; (26(9)):593-595.

    PMID: 39397508
  16. 16

    Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen.

    Lazzaroni MG, Airò P

    Journal of scleroderma and related disorders 2018; (3(3)):214-220 doi:10.1177/2397198318786158.

    PMID: 35382018

This page explains scleroderma subtypes and autoantibodies for educational purposes only. Always consult your rheumatologist to interpret your specific lab results and determine your proper screening protocol.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.